- All sections
- C - Chemistrymetallurgy
- C07D - Heterocyclic compounds
- C07D 319/18 - Ethylenedioxybenzenes, not substituted on the hetero ring
Patent holdings for IPC class C07D 319/18
Total number of patents in this class: 292
10-year publication summary
|
20
|
15
|
25
|
19
|
17
|
14
|
18
|
23
|
13
|
12
|
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Biosplice Therapeutics, Inc. | 160 |
10 |
| CHDI Foundation, Inc. | 107 |
9 |
| Agios Pharmaceuticals, Inc | 225 |
7 |
| Lapix Therapeutics, Inc. | 16 |
6 |
| Bristol-myers Squibb Company | 4751 |
5 |
| Cancer Research Technology Limited | 515 |
5 |
| Genzyme Corporation | 1367 |
5 |
| The Scripps Research Institute | 1340 |
5 |
| Taisho Pharmaceutical Co., Ltd. | 850 |
5 |
| Toyama Chemical Co., Ltd. | 88 |
5 |
| Acelot, Inc. | 16 |
5 |
| Enveric Biosciences Canada Inc. | 65 |
5 |
| F. Hoffmann-La Roche AG | 7819 |
4 |
| Merck Patent GmbH | 5729 |
4 |
| Allergan, Inc. | 2162 |
4 |
| BioMarin Pharmaceutical Inc. | 399 |
4 |
| ChemoCentryx, Inc. | 361 |
4 |
| Exonhit Therapeutics SA | 18 |
4 |
| Tianjin Chasesun Pharmaceutical Co., Ltd | 13 |
4 |
| The United States of America, as represented by the Secretary, Department of Health and Human Services | 3003 |
4 |
| Other owners | 188 |